Can Methods Developed for Interpreting Group-level Patient-reported Outcome Data be Applied to Individual Patient Management?
Journal
Medical care
ISSN: 1537-1948
Titre abrégé: Med Care
Pays: United States
ID NLM: 0230027
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
entrez:
16
4
2019
pubmed:
16
4
2019
medline:
28
4
2020
Statut:
ppublish
Résumé
Patient-reported outcome (PRO) data may be used at 2 levels: to evaluate impacts of disease and treatment aggregated across individuals (group-level) and to screen/monitor individual patients to inform their management (individual-level). For PRO data to be useful at either level, we need to understand their clinical relevance. To provide clarity on whether and how methods historically developed to interpret group-based PRO research results might be applied in clinical settings to enable PRO data from individual patients to inform their clinical management and decision-making. We first differentiate PRO-based decision-making required at group versus individual levels. We then summarize established group-based approaches to interpretation (anchor-based and distribution based), and more recent methods that draw on item calibrations and qualitative research methods. We then assess the applicability of these methods to individual patient data and individual-level decision-making. Group-based methods provide a range of thresholds that are useful in clinical care: some provide screening thresholds for patients who need additional clinical assessment and/or intervention, some provide thresholds for classifying an individual's level of severity of symptoms or problems with function, and others provide thresholds for meaningful change when monitoring symptoms and functioning over time during or after interventions. Availability of established cut-points for screening and symptom severity, and normative/reference values, may play into choice of PRO measures for use in clinical care. Translatability of thresholds for meaningful change is more problematic because of the greater reliability needed at the individual-level versus group-level, but group-based methods may provide lower bound estimates. Caution is needed to set thresholds above bounds of measurement error to avoid "false-positive changes" triggering unwarranted alerts and action in clinic. While there are some challenges in applying available methods for interpreting group-based PRO results to individual patient data and clinical care-including myriad contextual factors that may influence an individual patient's management and decision-making-they provide a useful starting point, and should be used pragmatically.
Sections du résumé
BACKGROUND
Patient-reported outcome (PRO) data may be used at 2 levels: to evaluate impacts of disease and treatment aggregated across individuals (group-level) and to screen/monitor individual patients to inform their management (individual-level). For PRO data to be useful at either level, we need to understand their clinical relevance.
PURPOSE
To provide clarity on whether and how methods historically developed to interpret group-based PRO research results might be applied in clinical settings to enable PRO data from individual patients to inform their clinical management and decision-making.
METHODS
We first differentiate PRO-based decision-making required at group versus individual levels. We then summarize established group-based approaches to interpretation (anchor-based and distribution based), and more recent methods that draw on item calibrations and qualitative research methods. We then assess the applicability of these methods to individual patient data and individual-level decision-making.
FINDINGS
Group-based methods provide a range of thresholds that are useful in clinical care: some provide screening thresholds for patients who need additional clinical assessment and/or intervention, some provide thresholds for classifying an individual's level of severity of symptoms or problems with function, and others provide thresholds for meaningful change when monitoring symptoms and functioning over time during or after interventions. Availability of established cut-points for screening and symptom severity, and normative/reference values, may play into choice of PRO measures for use in clinical care. Translatability of thresholds for meaningful change is more problematic because of the greater reliability needed at the individual-level versus group-level, but group-based methods may provide lower bound estimates. Caution is needed to set thresholds above bounds of measurement error to avoid "false-positive changes" triggering unwarranted alerts and action in clinic.
CONCLUSIONS
While there are some challenges in applying available methods for interpreting group-based PRO results to individual patient data and clinical care-including myriad contextual factors that may influence an individual patient's management and decision-making-they provide a useful starting point, and should be used pragmatically.
Identifiants
pubmed: 30985595
doi: 10.1097/MLR.0000000000001111
pii: 00005650-201905001-00008
pmc: PMC6467500
mid: NIHMS1522394
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
S38-S45Subventions
Organisme : NCI NIH HHS
ID : P30 CA015083
Pays : United States
Références
Med Care. 1999 May;37(5):469-78
pubmed: 10335749
J Clin Epidemiol. 1999 Sep;52(9):861-73
pubmed: 10529027
J Eval Clin Pract. 1999 Nov;5(4):401-16
pubmed: 10579704
Med Care. 2000 Feb;38(2):175-86
pubmed: 10659691
Health Technol Assess. 2000;4(5):1-120
pubmed: 10859208
Med Care. 2000 Sep;38(9 Suppl):II28-42
pubmed: 10982088
Pain. 2001 Nov;94(2):149-58
pubmed: 11690728
Mayo Clin Proc. 2002 Apr;77(4):371-83
pubmed: 11936935
J Clin Epidemiol. 2002 Sep;55(9):900-8
pubmed: 12393078
Med Care. 2003 May;41(5):582-92
pubmed: 12719681
Eval Health Prof. 2005 Jun;28(2):160-71
pubmed: 15851771
Eval Health Prof. 2005 Jun;28(2):172-91
pubmed: 15851772
Health Qual Life Outcomes. 2006 Aug 22;4:54
pubmed: 16925807
Qual Life Res. 2007 Feb;16(1):131-42
pubmed: 17033901
COPD. 2005 Mar;2(1):63-7
pubmed: 17136964
J Clin Epidemiol. 2008 Feb;61(2):102-9
pubmed: 18177782
Psychooncology. 2009 Nov;18(11):1129-38
pubmed: 19319920
J Clin Epidemiol. 2010 Mar;63(3):270-81
pubmed: 19716264
Eur J Haematol. 2010 Apr;84(4):345-53
pubmed: 20041946
Support Care Cancer. 2011 Nov;19(11):1753-60
pubmed: 20886240
J Clin Oncol. 2011 Jan 1;29(1):89-96
pubmed: 21098316
Expert Rev Pharmacoecon Outcomes Res. 2011 Apr;11(2):171-84
pubmed: 21476819
Eur J Cancer. 2012 Jul;48(11):1713-21
pubmed: 22418017
BMJ Qual Saf. 2014 Jun;23(6):508-18
pubmed: 24505110
BMJ Open. 2014 Jul 22;4(7):e005601
pubmed: 25052175
Qual Life Res. 2015 Oct;24(10):2457-72
pubmed: 26012839
Control Clin Trials. 1989 Dec;10(4):407-15
pubmed: 2691207
Support Care Cancer. 2016 Oct;24(10):4149-57
pubmed: 27165054
J Comp Eff Res. 2016 Aug;5(5):507-19
pubmed: 27427277
Qual Life Res. 2017 Feb;26(2):259-271
pubmed: 27469506
Cancer. 2017 May 15;123(10):1848-1859
pubmed: 28085201
Qual Life Res. 2017 Nov;26(11):2961-2971
pubmed: 28624901
Med Care. 2019 May;57 Suppl 5 Suppl 1:S8-S12
pubmed: 30985590
Med Care. 2019 May;57 Suppl 5 Suppl 1:S18-S23
pubmed: 30985592
Med Care. 2019 May;57 Suppl 5 Suppl 1:S24-S30
pubmed: 30985593
Med Care. 2019 May;57 Suppl 5 Suppl 1:S46-S51
pubmed: 30985596
Med Care. 2019 May;57 Suppl 5 Suppl 1:S85-S91
pubmed: 30985601
Arch Intern Med. 1982 May;142(5):879-82
pubmed: 7082113
Qual Life Res. 1995 Aug;4(4):293-307
pubmed: 7550178
J Gen Intern Med. 1997 Apr;12(4):254-5
pubmed: 9127232
J Clin Epidemiol. 1997 Aug;50(8):869-79
pubmed: 9291871
J Clin Oncol. 1998 Jan;16(1):139-44
pubmed: 9440735